pcDNA3-FLAG-MTOR-C1483F Citations (2)

Originally described in: A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM Cancer Discov. 2014 May;4(5):554-63. doi: 10.1158/2159-8290.CD-13-0929. Epub 2014 Mar 14. PubMed Journal

---

Articles Citing pcDNA3-FLAG-MTOR-C1483F

Articles
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR(T790M)-Mutant NSCLC. Park HR, Kim TM, Lee Y, Kim S, Park S, Ju YS, Kim M, Keam B, Jeon YK, Kim DW, Heo DS. J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02254-1. doi: 10.1016/j.jtho.2021.06.013. PubMed
mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Liu HJ, Du H, Khabibullin D, Zarei M, Wei K, Freeman GJ, Kwiatkowski DJ, Henske EP. Nat Commun. 2023 Mar 3;14(1):1214. doi: 10.1038/s41467-023-36881-7. PubMed

If you have published an article using this material, please email us at to have your article added to this page.